Skip to main content
Department of Neurosurgery

Recent Publications

Here you can find recent publications from the lab:

For a full publication list see PubMed: Soma Sengupta and Daniel Pomeranz Krummel

Publications in 2024

  • Ryan D., Bou Dargham T., Ikramuddin S., Shekhar S., Sengupta S., Feng W. (2024). Epidemiology, Pathophysiology, and Management of Cancer-Associated Ischemic Stroke. Cancers. 16(23):4016.
  • Kiang K.M., Wong K-H., Sengupta S., Lu Q.R. (2024). Developmental origins and oncogenesis in medulloblastoma. Annual Review of Neuroscience. Volume 48.
  • Wang B., Bukowski A., Kaidar-Person O., Choi J.M., Sasaki-Adams D.M., Jaikumar S., Higgins D.M., Ewend M.G., Sengupta S., Zagar T.M., Yanagihara T.K., Tepper J.E., Marks L.B., Shen C.J. (2024). Association between tumor location and toxicity outcomes after stereotactic radiosurgery for brain metastases. Journal of Neuro-Oncology. doi: 10.1007/s11060-024-04866-1.
  • Aulakh S, Xiu J, Hinton A, Darabi S, Demeure MJ, Sengupta S, Kesari S, Ashley DM, Sumrall AL, Glantz MJ, Spetzler D. Biological and prognostic relevance of epigenetic regulatory genes in high-grade gliomas. Neurooncol Adv. 2024 Oct 4;6(1):vdae169.

  • Perez N.M., Pensabene J.M., Galbo Jr P.M., Sadeghipour N., Xiu J., Moziak K., Yazejian R.M., Welch R.L., Bell W.R., Soma Sengupta S., Aulakh S., Eberhart C.G., Loeb D.M., Eskandar E., Zheng D., Zang X., Martin A.M. (2024). VISTA emerges as a promising target against immune evasion mechanisms in medulloblastoma. Cancers. 16(15):2629.

  • Sengupta S., Rao, R., Kaufman Z., Stuhlmiller T.J., Wong K.K., Kesari S., Shapiro M.A., Kramer G.A. (2024). A health care clinical data platform for rapid deployment of artificial intelligence and machine learning algorithms for cancer care and oncology. North Carolina Medical Journal. 85(4).

  • Bhattacharya D., Barille R., Toukam D.K., Gawali V.S., Kallay L., Ahmed T., Brown H., Rezvanian S., Karve A., Desai P.B., Medvedovic M., Wang K., Ionascu D., Harun N., Vallabhapurapu S., Wang C., Qi X., Baschnagel A.M., Kritzer J.A., Cook J.M., Pomeranz Krummel D.A., Sengupta S. (2024). GABA(A) receptor activation drives GABARAP-Nix mediated autophagy to radiation-sensitize primary and brain-metastatic lung adenocarcinoma tumors. Cancers. 16(18): 3167.

  • Rebola C., Rao R., Koehler A., et al. (2024). Pilot testing of CAN Digital Apps to improve the quality of life of cancer and benign brain tumor survivors. Journal of Neuro and Oncology Research. 4:1-11.
  • Lin A.L., Rudneva V.A., Richards A.L. et al. (2024). Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors. Acta Neuropathol. 147:85.
  • Rao R., Mohammed C., Alschuler L., Pomeranz Krummel D., Sengupta S. (2024). Phytochemical modulation of ion channels in oncologic symptomatology. Cancers. 16(9):1786.
  • Pun S., Prakash A., Demaree D., Pomeranz Krummel D., Sciumè G., Sengupta S., Barrile R. (2024). Rapid biofabrication of an advanced microphysiological system mimicking phenotypical heterogeneity and drug resistance in glioblastoma. Adv Healthc Mater. e2401876.
  • Behrmann C., Ennis K., Sarma P., Wetzel C., Clark N., Von Handorf K., Vallabhapurapu S., Reigle J., Meller J., Czyzyk-Krzeska M., Kendler A., Qi X., Sarkaria J., Medvedovic M., Sengupta S., Dasgupta B., Plas D. (2024). Coordinated targeting of S6K1/2 and AXL in PTEN-deficient glioblastoma to disrupt pyrimidine biosynthesis. Cancer Research Communications. 4(8):2215-2227.
  • Desai P.B., Karve A., Zawit M., Arora P., Dave N., Awosika J., Li N., Fuhrman B., Medvedovic M., Sallans L., Kendler A., DasGupta B., Plas D., Curry R., Zuccarello M., Chaudhary R., Sengupta S., Wise-Draper T.M. (2024). A Phase 0/1 pharmacokinetic and pharmacodynamics and safety and tolerability study of letrozole in combination with standard therapy in recurrent high-grade gliomas. Clin Cancer Res. 30(10):2068-2077.
  • Karve AS, Desai JM, Gadgil SN, Dave N, Wise-Draper TM, Gudelsky GA, Phoenix TN, DasGupta B, Yogendran L, Sengupta S, Plas DR, Desai PB. (2024). A review of approaches to potentiate the activity of temozolomide against glioblastoma to overcome resistance. Int J Mol Sci. 25(6):3217.
  • Cioffi G., Waite K.A., Dmukauskas M., Glantz M., Aulakh S., Nicolaides T., Sengupta S., Xiu J., Barnholtz-Sloan J.S. (2024). Sex differences in Glioblastoma response to treatment: impact of MGMT methylation. Neuro-Oncology Advances. 6(1): vdae031.
  • Rao R., Shah S., Rothman Y., Peerboom D., Zuccarello M., Yogendran L., Sengupta S. (2024). Osimertinib in combination with Bevacizumab for EGFR mutated recurrent Glioblastoma (GBM): a case report. J Neuro Onco Res. 4(1):1-7.

Publications in 2023

  • Xin D.E., Liao Y., Rao R., Ogurek S., Sengupta S., Xin M., Seibel W.L., Graham R.T., Koschmann C., Lu Q.R. (2023). Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse intrinsic pontine gliomas and synergizes with ONC201. Neuro-Oncology. 26(4):735-748.
  • Hall J., Lui K., Tan X., Shumway J., Collichio F., Moschos S., Sengupta S., Chaudhary R., Quinsey C., Jaikumar S., Forbes J., Andaluz N., Zuccarello M., Struve T., Vatner R., Pater L., Breneman J., Weiner A., Wang K., Shen C. (2023). Factors associated with radiation necrosis and intracranial control in patients treated with Immune Checkpoint Inhibitors and Stereotactic Radiotherapy. Radiotherapy & Oncology. 189:109920.
  • Johnson M., Bell A., Lauing K.L., Ladomersky E., Zhai L., Penco-Campillo M., Shah Y., Mauer E., Xiu J., Nicolaides T., Drumm M., McCortney K., Elemento O., Kim M., Bommi P., Low J.T., Memon R., Wu J., Zhao J., Mi X., Glantz M.J., Sengupta S., Castro B., Yamini B., Horbinski C., Baker D.J., Walunas T.L., Schiltz G.E., Lukas R.V., Wainwright D.A. (2023). Advanced age in humans and mouse models of glioblastoma show decreased survival from extratumoral influence. Clinical Cancer Research. 29(23):4973-4989.
  • Rao R., Koehler A., Khoury J., Desai K., Rothman Y., Yogendran L.V., Alwell K., Shaughnesy E., Feng W., Demel W., Sengupta S. (2023). A retrospective pilot study suggesting an increased prevalence of stroke in patients with breast cancer in the greater Cincinnati/Northern Kentucky region. Neurology & Neurological Sciences: Open Access. 6(2):1032.
  • Kallay L., Gawali V.S., Toukam D.K., Bhattacharya D., Jenkins A., Sengupta S., Pomeranz Krummel D.A. (2023). Screening ion channels in cancer cells. Journal of Visualized Experiments. 196:e65427.
  • Darabi S., Xiu J., Samec T., Kesari S., Magee D., Carrillo J., Aulakh S., Walsh K.M., Sengupta S., Sumrall A., Spetzler D., Glantz M., Demeure M.J. (2023). Capicua (CIC) mutations in gliomas in association with MAPK activation for exposing a potential therapeutic target. Medical Oncology. 40:197.
  • Sengupta S. (2023). Integrative neuro-oncology for brain tumor patients. Journal of Neuro-Oncology. 163(1):289-290.
  • Rao R,, Patel A., Hanchate K., Robinson E., Edwards A., Shah S., Higgins D., Haworth K.J., Brandon, Lucke-Wold B., Pomeranz Krummel D., Sengupta S. (2023). Advances in Focused Ultrasound for the treatment of brain tumors. Tomography. 9(3):1094-1109.
  • Ranjan T*., Sengupta S*., Glantz M.J., Green R.M., Yu A., Aregawi D., Chaudhary R., Chen R., Zuccarello M., Lu-Emerson C., Moulding H.D., Belman N., Glass J., Mammoser A., Anderson M., Valluri J., Marko N., Schroeder J., Jubelirer S., Chow F., Claudio P.P., Alberico A.M., Lirette S.T., Denning K.L., Howard C.M. (2023). Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial. Cell Reports Medicine. 4(5):101025 (*co-first authors).
  • Hey G., Rao R., Carter A., Reddy A., Valle D., Patel A., Patel D., Lucke-Wold B., Pomeranz Krummel D., Sengupta S. (2023). Ligand-gated ion channels: prognostic and therapeutic implications for gliomas. Journal of Personalized Medicine.13(5):853.
  • Lechpammer M., Mohammedi A., Pomeranz Krummel D.A., Sengupta S. (2023). Chapter 9 – Lessons learned from evolving frameworks in adult glioblastoma, Editor(s): Alberto J. Espay, Handbook of Clinical Neurology. 192:131-140.